Trials / Completed
CompletedNCT04330872
An Investigation Into The Impact Of Enteric Coated Of Aspirin In Patients With Newly Diagnosed Ischemic Stroke.
An Investigation Into The Impact Of Enteric Coated Of Aspirin In Patients With Newly Diagnosed Ischemic Stroke. Non-randomized Interventional Controlled Clinical Trial.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Hamad Medical Corporation · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Uncertainty remains regarding the impact of enteric-coated (EC) aspirin as it relates to the reduction of CV risk. We hypothesize that EC formulation based on the previous report may blunt aspirin response as evidenced by reduced Thromboxane A2 (TXA 2) levels in diabetic patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enteric Coated Aspirin Tablet | Study participants will be assigned to receive either EC Aspirin and will be required to continue taking them throughout the study (three days). |
| DRUG | Plain Aspirin | Study participants will be assigned to receive either Plain Aspirin and will be required to continue taking them throughout the study (three days). |
Timeline
- Start date
- 2019-08-26
- Primary completion
- 2020-01-04
- Completion
- 2020-03-04
- First posted
- 2020-04-02
- Last updated
- 2020-04-02
Locations
1 site across 1 country: Qatar
Source: ClinicalTrials.gov record NCT04330872. Inclusion in this directory is not an endorsement.